secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001104659-25-005291
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune BLA for RP1+nivolumab in advanced melanoma accepted with Priority Review; PDUFA July 22, 2025
--------------------------------------------------------------------------------

- FDA accepted BLA for RP1 (vusolimogene oderparepvec) plus nivolumab for advanced melanoma; granted Priority Review.
- PDUFA action date set for July 22, 2025; no advisory committee meeting currently planned.
- BLA supported by primary analysis from IGNYTE trial in anti-PD-1 failed melanoma patients.
- Confirmatory Phase 3 IGNYTE-3 trial ongoing with over 100 planned sites globally.
- Replimune previously received Breakthrough Therapy designation for this combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925005291/0001104659-25-005291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925005291/tm254066d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-005291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer